论文部分内容阅读
目的：分析乙肝表面抗原 (HBsAg)阳性与 HBsAg阴性肝癌住院患者的临床特点及治疗干预对肝功能的影响。 方法：对 291例原发性肝癌患者，全部测定肝炎标志物 ,根据结果将患者分为 HBsAg阳性组及 HBsAg阴性组 ,比较两组患者的年龄、性别、甲胎蛋白（ AFP）及肝功能情况 ,并比较治疗前后谷丙转氨酶（ ALT）的变化。结果：原发性肝癌患者 HBsAg阳性 254例 (87.3％ );HBsAg阳性组 AFP阳性率 78.3％ ,而 HBsAg阴性组 AFP阳性率为 34.2％ ,两组间差异有统计学意义 ;手术治疗患者 ALT变化以 HBsAg阳性组明显 ;手术切除后及肝动脉栓塞化疗 (TAE)后 ALT均有明显升高，具有统计学意义，但两组间比较无显著性差异。结论： HBV是原发性肝癌发生的重要病因 ,原发性肝癌患者中 ,AFP升高与乙型病毒性肝炎有关 ;肝叶切除手术及 TAE均可加重肝功能损害。
Objective: To analyze the clinical features of hepatitis B surface antigen (HBsAg) positive and hospitalized patients with HBsAg negative liver cancer and the effect of therapeutic intervention on liver function. Methods: All 291 patients with primary liver cancer were tested for hepatitis markers. According to the results, the patients were divided into HBsAg-positive group and HBsAg-negative group. The age, gender, alpha-fetoprotein (AFP) and liver function were compared between the two groups. , and compare changes in alanine aminotransferase (ALT) before and after treatment. Results: HBsAg positive cases were 254 (87.3%) in patients with primary liver cancer; AFP positive rate was 78.3% in HBsAg positive group, and AFP positive rate was 34.2% in HBsAg negative group. The difference between the two groups was statistically significant; In the HBsAg-positive group, there was a significant increase in ALT after surgical resection and after hepatic artery embolization chemotherapy (TAE), but there was no significant difference between the two groups. Conclusions: HBV is an important cause of primary hepatocellular carcinoma. Among patients with primary liver cancer, the increase of AFP is associated with viral hepatitis B; liver lobectomy and TAE can aggravate liver damage.